Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
doi: https://doi.org/10.1101/2022.07.12.22277548

Article usage

Article usage: July 2022 to January 2025

AbstractFullPdf
Jul 2022346281377
Aug 202291879184
Sep 20225137375
Oct 20225196355
Nov 20223075248
Dec 20222866135
Jan 20232936035
Feb 20231704323
Mar 20231703531
Apr 20231222426
May 20231323320
Jun 20231062615
Jul 2023823114
Aug 20231008727
Sep 20231485824
Oct 2023913419
Nov 202381469
Dec 2023673113
Jan 2024502912
Feb 2024581811
Mar 202455139
Apr 2024451114
May 2024631315
Jun 2024623123
Jul 2024471619
Aug 2024632214
Sep 2024652015
Oct 2024491524
Nov 2024532220
Dec 2024651630
Jan 202545913
Back to top
Posted July 13, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Inhaled Fluticasone for Outpatient Treatment of Covid-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group, Susanna Naggie
medRxiv 2022.07.12.22277548; doi: https://doi.org/10.1101/2022.07.12.22277548
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area